| abstract |
Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof aryl olefinic azacyclic compounds and aryl acetylenic azacylic compounds, including pyridyl olefinic cycloalkylamines and pyridyl acetyleni c cycloalkylamines. Exemplary compounds include (S)-(E)-3-(3-pyrrolidin-2-yl- prop-1-enyl)pyridine, (S)-(E)-3-(2-pyrrolidin-2-ylvinyl)pyridine, 3-(2- pyrrolidin-2-ylethenyl)pyridine, 3-(3-pyrrolidin-2-ylprop-1-enyl)pyridine, 3 - (2-(2-azetidinyl)ethenyl)pyridine, 3-(3-(2-azetidinyl) prop-1-enyl)pyridine, 2- (2-(3-pyridyl)ethenyl)-1-azabicyclo[3.3.0]octane, 2-(3-(3-pyridyl)prop-2-eny l)- 1-azabicyclo[3.3.0]octane, 3-(2-(3-pyridyl)ethenyl)-2- azabicyclo[2.2.1]heptane, 3-(3-(3-pyridyl)prop-2-enyl)-2- azabicyclo[2.2.1]heptane, 2-(2-(3-pyridyl)ethenyl)-7-azabicyclo[2.2.1]heptan e, 2-(3-(3-pyridyl)prop-2-enyl)-7-azabicyclo[2.2.1]heptane, 2-(2-(3- pyridyl)ethenyl)quinuclidine and 2-(3-(3-pyridyl)prop-2-enyl)quinuclidine.</ SDOAB> |